Memo Therapeutics AG, a late-stage biotech company developing a best-in-class BKV-neutralizing anti-body for BKV infection in kidney transplantation, raised CHF20 million as part of an extension of its series C financing round, bringing the total amount raised in the funding round to CHF 45m. Ysios Capital and Kurma Partners led the extension round and joined the existing series C investors. The proceeds will be used to expand the Phase II clinical development of Memo Therapeutics AG's best-in-class anti-BK Virus antibody to become the largest study ever conducted for BK virus infection in kidney transplantation.

The VISCHER team that advised the main investors in this transaction included Dr. Matthias Staehelin (Partner, Corporate/M&A), Vincent S. Reardon (Managing Associate, Corporate/M&A), Lucas M. Sturzenegger (Associate, Corporate/M&A) and Adrian Briner (Counsel, Tax).

Author: Matthias Staehelin